Clinical Trial Update: Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD) [Phase 3]

View source ↗

Summary

Phase 3 trial update on FURESTEM-AD Injection for moderate to severe atopic dermatitis, with safety and efficacy data yet to be determined.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• FURESTEM-AD

Snippet

Sponsor: Kang Stem Biotech Co., Ltd. | Conditions: Dermatitis, Atopic | Phase 3 | Status: UNKNOWN